Xenetic Biosciences, Inc.
(NASDAQ : XBIO)

( )
XBIO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.88%93.921.3%$988.55m
BIIBBiogen Inc.
2.45%229.891.3%$619.18m
AMGNAmgen Inc.
1.22%180.481.3%$474.61m
GILDGilead Sciences, Inc.
2.13%64.140.9%$448.87m
ILMNIllumina, Inc.
1.49%319.203.5%$295.43m
REGNRegeneron Pharmaceuticals, Inc.
2.80%349.992.6%$291.08m
VRTXVertex Pharmaceuticals Incorporated
1.18%174.611.9%$236.35m
ALXNAlexion Pharmaceuticals, Inc.
4.30%135.682.0%$176.60m
EXASExact Sciences Corporation
0.27%95.3925.3%$169.11m
AAgilent Technologies, Inc.
1.23%76.721.6%$147.38m
SRPTSarepta Therapeutics, Inc.
1.74%120.2214.7%$129.47m
ONCESpark Therapeutics, Inc.
0.64%111.3811.2%$116.56m
INCYIncyte Corporation
0.57%73.942.5%$97.68m
IONSIonis Pharmaceuticals, Inc.
0.72%73.868.3%$96.82m
BMRNBioMarin Pharmaceutical Inc.
-0.21%85.314.3%$92.88m

Company Profile

Xenetic Biosciences, Inc. engages in the discovery, research, and development of next generation biologic drugs and novel orphan oncology therapeutics. Its lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod), which focuses on the treatment of progesterone resistant endometrial cancer. It also offers proprietary drug development platform, PolyXen, which enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.